In the phase 2, open-label, single-arm QUADRA study, results of which were presented at the 2018 ASCO, 463 patients with ovarian cancer were enrolled and treated with niraparib. The objective response rate (ORR) in the heavily pretreated (4th line or later) patients carrying BRCA mutation was 30.9% (17/55). In the subgroup analysis of BRCA-mutated patients, ORR was 38.9% (7/18) and 27% (10/37) in the platinum-sensitive and platinum-resistant/refractory group respectively. Additionally, niraparib showed 27.5% (14/51) ORR in platinum-sensitive patients with homologous recombinant deficiency (HRD). Taken together, niraparib demonstrated a clinical benefit in heavily pretreated patients with HRD-positive ovarian cancer.
Source : Journal of Clinical Oncology 36, 2018 (suppl; abstr 5514)